Analyst Ratings (USA)
The current analyst outlook remains cautiously positive, with positive recommendations accounting for most of today’s coverage and upgrades continuing to outnumber downgrades. However, price-target reductions exceeded increases, indicating that analysts are becoming more disciplined about valuations and near-term earnings expectations. Technology, healthcare and biotechnology continue to attract the strongest interest, while energy, financial and consumer stocks show a more mixed outlook. Overall, sentiment remains constructive, but analysts are increasingly favouring companies with clear earnings momentum, strong balance sheets and reliable growth prospects.
Wall Street analysts released 199 rating and price-target actions covering 160 U.S.-listed companies on September 22, 2026. The daily activity included 11 upgrades, 5 downgrades, 32 target increases, 38 target reductions, 34 new coverage initiations, 12 newly stated price targets and 67 reiterated ratings.
199 Analyst Updates
Abivax (ABVX): Barclays maintained its Overweight rating with a US$148.00 price target.
Abivax (ABVX): Truist Financial lowered its price target to US$151.00 from US$155.00 while retaining a Buy rating.
Abivax (ABVX): Wedbush lowered its price target to US$118.00 from US$140.00 while retaining a Neutral rating.
Adaptive Biotechnologies (ADPT): BTIG raised its price target to US$34.00 from US$25.00 while retaining a Buy rating.
Adaptive Biotechnologies (ADPT): National Bank Financial set a US$34.00 price target.
Advanced Energy Industries (AEIS): Cantor Fitzgerald maintained its Overweight rating.
Alaska Air Group (ALK): UBS maintained its Buy rating and raised its price target to US$54.00 from US$52.00.
Alcoa (AA): Freedom Broker raised its price target to US$76.00 from US$64.00 while retaining a Buy rating.
Alkermes (ALKS): Robert W. Baird raised its price target to US$61.00 from US$58.00 while retaining an Outperform rating.
Alkermes (ALKS): RBC Capital Markets maintained its Outperform rating with a US$56.00 price target.
Allegion (ALLE): Evercore maintained its Outperform rating with a US$180.00 price target.
Amphenol (APH): BNP Paribas Exane raised its price target to US$110.00 from US$107.50 while retaining an Outperform rating.
Amrize (AMRZ): UBS lowered its price target to US$42.00 from US$57.00 while retaining a Neutral rating.
AnaptysBio (ANAB): Cantor Fitzgerald maintained its Overweight rating.
AnaptysBio (ANAB): HC Wainwright maintained its Buy rating with a US$95.00 price target.
Anixa Biosciences (ANIX): HC Wainwright lowered its price target to US$6.00 from US$7.00 while retaining a Buy rating.
Antero Midstream (AM): Capital One Financial upgraded the stock to Overweight and set a US$25.00 price target.
ArriVent BioPharma (AVBP): Cantor Fitzgerald maintained its Overweight rating.
Atlanticus (ATLC): BTIG maintained its Buy rating with a US$179.00 price target.
AvePoint (AVPT): Cantor Fitzgerald maintained its Overweight rating.
BankUnited (BKU): Citigroup maintained its Sell rating.
Bicara Therapeutics (BCAX): HSBC downgraded the stock to Equal Weight.
Bilibili (BILI): BNP Paribas Exane initiated coverage with an Outperform rating and a US$23.00 price target.
BitMine Immersion Technologies (BMNR): B. Riley raised its price target to US$34.00 from US$30.00 while retaining a Buy rating.
Brinker International (EAT): Northcoast Research upgraded the stock to Buy and set a US$275.00 price target.
Butterfly Network (BFLY): Needham initiated coverage with a Buy rating and a US$10.00 price target.
Cal-Maine Foods (CALM): Stephens set a US$80.00 price target with an Equal Weight rating, compared with a previous target of US$90.00.
Camtek (CAMT): Cantor Fitzgerald maintained its Neutral rating with a US$175.00 price target.
Capri (CPRI): Jefferies maintained its Hold rating.
Carnival (CCL): Deutsche Bank set a US$32.00 price target.
Carnival (CCL): TD Cowen lowered its price target to US$32.00 from US$34.00 while retaining a Buy rating.
Celldex Therapeutics (CLDX): Cantor Fitzgerald raised its price target to US$72.00 from US$61.00 while retaining an Overweight rating.
Celldex Therapeutics (CLDX): HC Wainwright raised its price target to US$64.00 from US$42.00 while retaining a Buy rating.
Celldex Therapeutics (CLDX): Stifel Nicolaus set a US$68.00 price target.
ChargePoint (CHPT): UBS maintained its Neutral rating and raised its price target to US$9.00 from US$8.00.
Chord Energy (CHRD): UBS lowered its price target to US$184.00 from US$189.00 while retaining a Buy rating.
Cintas (CTAS): Citigroup maintained its Sell rating and raised its price target to US$180.00 from US$175.00.
Cisco Systems (CSCO): Piper Sandler lowered its price target to US$125.00 from US$132.00 while retaining a Neutral rating.
Coinbase Global (COIN): William Blair maintained its Outperform rating.
Columbia Banking System (COLB): Citigroup lowered its price target to US$31.00 from US$32.00 while retaining a Neutral rating.
Connect Biopharma (CNTB): Oppenheimer lowered its price target to US$5.00 while retaining an Outperform rating.
Constellation Brands (STZ): Barclays lowered its price target to US$122.00 from US$132.00 while retaining an Equal Weight rating.
Constellation Brands (STZ): Citigroup lowered its price target to US$165.00 from US$185.00 while retaining a Buy rating.
Costco Wholesale (COST): Evercore maintained its Outperform rating.
Crane NXT (CXT): Jefferies initiated coverage with a Buy rating and a US$60.00 price target.
CRH (CRH): UBS lowered its price target to US$135.00 from US$147.00 while retaining a Buy rating.
CVRx (CVRX): Canaccord Genuity set a US$5.00 price target.
CVS Health (CVS): UBS maintained its Buy rating.
D.R. Horton (DHI): BTIG maintained its Buy rating with a US$174.00 price target.
D.R. Horton (DHI): Keefe, Bruyette & Woods lowered its price target to US$160.00 from US$167.00 while retaining a Market Perform rating.
Darling Ingredients (DAR): UBS raised its price target to US$88.00 from US$78.00 while retaining a Buy rating.
Deep Fission (FISN): Roth Capital initiated coverage with a Buy rating and a US$18.00 price target.
Driven Brands (DRVN): Barclays initiated coverage with an Equal Weight rating and a US$14.00 price target.
East West Bancorp (EWBC): Citigroup lowered its price target to US$152.00 from US$156.00 while retaining a Buy rating.
Eldorado Gold (EGO): Bank of America upgraded the stock to Buy and raised its price target to US$54.00 from US$32.00.
Elemental Royalty (ELE): HC Wainwright lowered its price target to US$31.00 from US$33.00 while retaining a Buy rating.
Eli Lilly and Company (LLY): TD Cowen maintained its Buy rating with a US$1,250.00 price target.
Endava (DAVA): Deutsche Bank lowered its price target to US$2.00 from US$3.00 while retaining a Hold rating.
Endava (DAVA): TD Cowen maintained its Hold rating with a US$3.50 price target.
Endava (DAVA): William Blair downgraded the stock to Underperform.
Energy Transfer (ET): Capital One Financial initiated coverage with an Overweight rating and a US$26.00 price target.
Energy Transfer (ET): Melius Research initiated coverage with a Hold rating and a US$25.00 price target.
Entera Bio (ENTX): Cantor Fitzgerald initiated coverage with an Overweight rating.
Enterprise Products Partners (EPD): Capital One Financial initiated coverage with an Equal Weight rating and a US$42.00 price target.
Enterprise Products Partners (EPD): Melius Research initiated coverage with a Hold rating and a US$42.00 price target.
Enterprise Products Partners (EPD): RBC Capital Markets maintained its Outperform rating with a US$42.00 price target.
Equifax (EFX): Wells Fargo lowered its price target to US$200.00 from US$212.00 while retaining an Overweight rating.
Ericsson (ERIC): Morgan Stanley downgraded the stock to Underweight and lowered its price target to US$9.00 from US$11.00.
Essent Group (ESNT): BTIG initiated coverage with a Neutral rating.
Everest Group (EG): Rosenblatt Securities set a US$455.00 price target.
Everest Group (EG): RBC Capital Markets initiated coverage with an Outperform rating and a US$455.00 price target.
Exelon (EXC): Argus lowered its price target to US$49.00 from US$52.00 while retaining a Buy rating.
Fair Isaac (FICO): Wells Fargo lowered its price target to US$1,350.00 from US$1,450.00 while retaining an Overweight rating.
Ferrovial (FER): Morgan Stanley maintained its Overweight rating.
Fifth Third Bancorp (FITB): Citigroup upgraded the stock to Buy and raised its price target to US$62.00 from US$59.00.
First Horizon (FHN): Citigroup lowered its price target to US$28.00 from US$28.50 while retaining a Buy rating.
First Solar (FSLR): GLJ Research set a US$250.00 price target.
FormFactor (FORM): Cantor Fitzgerald maintained its Overweight rating.
Forward Industries (FWDI): B. Riley raised its price target to US$11.00 from US$9.00 while retaining a Buy rating.
GE HealthCare Technologies (GEHC): Needham initiated coverage with a Buy rating and a US$93.00 price target.
Glaukos (GKOS): Jefferies raised its price target to US$210.00 from US$190.00 while retaining a Buy rating.
GRAIL (GRAL): Robert W. Baird raised its price target to US$118.00 from US$96.00 while retaining an Outperform rating.
Gulfport Energy (GPOR): Pickering Energy Partners initiated coverage with an Outperform rating.
Hancock Whitney (HWC): Citigroup lowered its price target to US$86.00 from US$87.00 while retaining a Buy rating.
HeartBeam (BEAT): HC Wainwright downgraded the stock to Neutral.
Heartflow (HTFL): Canaccord Genuity raised its price target to US$56.00 from US$45.00 while retaining a Buy rating.
Heritage Financial (HFWA): Brean Capital upgraded the stock to Buy and set a US$33.00 price target.
Heritage Financial (HFWA): Capital One Financial set a US$33.00 price target.
Hinge Health (HNGE): Robert W. Baird raised its price target to US$90.00 from US$85.00 while retaining a Neutral rating.
Hyperfine (HYPR): BTIG maintained its Buy rating with a US$2.00 price target.
IDEAYA Biosciences (IDYA): Cantor Fitzgerald maintained its Overweight rating.
Incyte (INCY): RBC Capital Markets maintained its Sector Perform rating with a US$109.00 price target.
Ionis Pharmaceuticals (IONS): JPMorgan lowered its price target to US$70.00 from US$76.00 while retaining an Overweight rating.
IonQ (IONQ): Wedbush maintained its Outperform rating with a US$75.00 price target.
iRadimed (IRMD): Needham initiated coverage with a Hold rating.
Johnson & Johnson (JNJ): UBS maintained its Buy rating.
KBR (KBR): Oppenheimer lowered its price target to US$50.00 from US$60.00 while retaining an Outperform rating.
KeyCorp (KEY): Citigroup maintained its Neutral rating.
Kinder Morgan (KMI): Capital One Financial initiated coverage with an Equal Weight rating and a US$36.00 price target.
Kinder Morgan (KMI): Melius Research initiated coverage with a Buy rating and a US$38.00 price target.
Kinder Morgan (KMI): RBC Capital Markets raised its price target to US$36.00 from US$35.00 while retaining a Sector Perform rating.
KindlyMD (NAKA): B. Riley raised its price target to US$13.00 from US$11.00 while retaining a Buy rating.
Kraft Heinz (KHC): TD Cowen maintained its Hold rating with a US$22.00 price target.
Kymera Therapeutics (KYMR): Stifel Nicolaus raised its price target to US$152.00 from US$132.00 while retaining a Buy rating.
Lennar (LEN): Keefe, Bruyette & Woods lowered its price target to US$75.00 from US$85.00 while retaining an Underperform rating.
Lexeo Therapeutics (LXEO): Raymond James maintained its Strong Buy rating.
Liftoff Mobile (LFTO): Piper Sandler initiated coverage with a Neutral rating and a US$19.00 price target.
Lipocine (LPCN): Cantor Fitzgerald maintained its Overweight rating.
Lithia Motors (LAD): Citigroup lowered its price target to US$409.00 from US$455.00 while retaining a Buy rating.
Maze Therapeutics (MAZE): BTIG maintained its Buy rating with a US$46.00 price target.
McGraw Hill (MH): BTIG maintained its Buy rating with a US$17.00 price target.
Meta Platforms (META): Bank of America maintained its Buy rating with a US$810.00 price target.
Meta Platforms (META): Jefferies raised its price target to US$875.00 from US$710.00 while retaining a Buy rating.
MetLife (MET): Piper Sandler upgraded the stock to Overweight and raised its price target to US$110.00 from US$99.00.
MGIC Investment (MTG): BTIG initiated coverage with a Neutral rating.
Microsoft (MSFT): Oppenheimer raised its price target to US$570.00 from US$515.00 while retaining an Outperform rating.
Moderna (MRNA): UBS maintained its Neutral rating.
Motorola Solutions (MSI): Piper Sandler raised its price target to US$531.00 from US$530.00 while retaining an Overweight rating.
NetEase (NTES): BNP Paribas Exane initiated coverage with an Outperform rating and a US$180.00 price target.
Netflix (NFLX): BMO Capital Markets maintained its Outperform rating.
Netflix (NFLX): HSBC downgraded the stock to Hold and lowered its price target to US$76.00 from US$96.00.
Nextpower (NXT): Robert W. Baird lowered its price target to US$116.00 from US$156.00 while retaining an Outperform rating.
NMI (NMIH): BTIG initiated coverage with a Buy rating and a US$54.00 price target.
NVR (NVR): BTIG set a US$7,125.00 price target.
Obsidian Therapeutics (OBX): Leerink Partners initiated coverage with an Outperform rating and a US$32.00 price target.
Okta (OKTA): Robert W. Baird raised its price target to US$200.00 from US$185.00 while retaining an Outperform rating.
Okta (OKTA): Scotiabank raised its price target to US$190.00 from US$165.00 while retaining a Sector Outperform rating.
Old National Bancorp (ONB): Citigroup lowered its price target to US$30.00 from US$31.00 while retaining a Buy rating.
Omeros (OMER): Cantor Fitzgerald upgraded the stock to Overweight and set a US$22.00 price target.
ON (ONON): Goldman Sachs maintained its Buy rating.
ONEOK (OKE): Capital One Financial initiated coverage with an Overweight rating and a US$110.00 price target.
Option Care Health (OPCH): UBS maintained its Buy rating.
Paramount Skydance (PSKY): Citizens JMP maintained its Market Outperform rating with a US$14.00 price target.
Paramount Skydance (PSKY): Morgan Stanley raised its price target to US$11.50 from US$10.00 while retaining an Overweight rating.
Pharming Group (PHAR): HC Wainwright maintained its Buy rating with a US$37.00 price target.
Pilgrim’s Pride (PPC): UBS maintained its Neutral rating.
Popular (BPOP): Citigroup lowered its price target to US$192.00 from US$200.00 while retaining a Buy rating.
Priority Technology (PRTH): Keefe, Bruyette & Woods raised its price target to US$8.00 from US$6.50 while retaining a Market Perform rating.
Prosperity Bancshares (PB): Citigroup lowered its price target to US$77.00 from US$79.00 while retaining a Neutral rating.
PTC Therapeutics (PTCT): Cantor Fitzgerald raised its price target to US$137.00 from US$130.00 while retaining an Overweight rating.
Q2 (QTWO): Piper Sandler maintained its Overweight rating with a US$82.00 price target.
Quince Therapeutics (QNCX): Citizens JMP upgraded the stock to Outperform and set a US$77.00 price target.
Radian Group (RDN): BTIG initiated coverage with a Buy rating and a US$48.00 price target.
RadNet (RDNT): Raymond James maintained its Strong Buy rating.
Ralliant (RAL): Evercore maintained its Outperform rating.
Real Brokerage (REAX): JonesTrading maintained its Buy rating with a US$40.00 price target.
RenaissanceRe (RNR): Jefferies upgraded the stock to Market Outperform.
RenaissanceRe (RNR): RBC Capital Markets initiated coverage with a Sector Perform rating and a US$365.00 price target.
Rush Street Interactive (RSI): Citigroup maintained its Market Outperform rating.
Rush Street Interactive (RSI): Citizens JMP maintained its Market Outperform rating with a US$34.00 price target.
RxSight (RXST): Bank of America lowered its price target to US$5.50 from US$6.50 while retaining an Underperform rating.
RxSight (RXST): Jefferies lowered its price target to US$5.75 from US$6.50 while retaining a Hold rating.
Sandisk (SNDK): Rosenblatt Securities initiated coverage with a Buy rating and a US$2,400.00 price target.
SAP (SAP): Citigroup maintained its Buy rating.
SAP (SAP): Jefferies maintained its Buy rating with a US$260.00 price target.
Sharplink Gaming (SBET): B. Riley maintained its Buy rating and raised its price target to US$14.00 from US$12.00.
Sherwin-Williams (SHW): RBC Capital Markets maintained its Outperform rating with a US$420.00 price target.
SiriusPoint (SPNT): RBC Capital Markets initiated coverage with an Outperform rating and a US$30.00 price target.
Solana (HSDT): B. Riley raised its price target to US$4.00 from US$3.50 while retaining a Buy rating.
SoundHound AI (SOUN): Piper Sandler lowered its price target to US$6.00 from US$7.00 while retaining a Neutral rating.
STAAR Surgical (STAA): Jefferies lowered its price target to US$23.00 from US$28.00 while retaining a Buy rating.
Strategy (MSTR): B. Riley raised its price target to US$195.00 from US$175.00 while retaining a Buy rating.
Strive (ASST): B. Riley raised its price target to US$33.00 from US$26.00 while retaining a Buy rating.
Stryker (SYK): TD Cowen lowered its price target to US$298.00 from US$355.00 while retaining a Hold rating.
Summit Therapeutics (SMMT): Cantor Fitzgerald maintained its Overweight rating.
Terrestrial Energy (IMSR): Roth Capital initiated coverage with a Buy rating and a US$15.00 price target.
Texas Capital Bancshares (TCBI): Citigroup lowered its price target to US$104.00 from US$107.00 while retaining a Neutral rating.
Tiziana Life Sciences (TLSA): BTIG maintained its Buy rating.
Travere Therapeutics (TVTX): HC Wainwright maintained its Buy rating with a US$67.00 price target.
Travere Therapeutics (TVTX): Wedbush maintained its Outperform rating with a US$76.00 price target.
Turning Point Brands (TPB): Oppenheimer lowered its price target to US$90.00 from US$130.00 while retaining an Outperform rating.
Twilio (TWLO): Rosenblatt Securities raised its price target to US$290.00 from US$275.00 while retaining a Buy rating.
Twilio (TWLO): TD Cowen raised its price target to US$300.00 from US$260.00 while retaining a Buy rating.
Tyra Biosciences (TYRA): HC Wainwright lowered its price target to US$29.00 from US$30.00 while retaining a Buy rating.
Tyra Biosciences (TYRA): Oppenheimer maintained its Outperform rating and lowered its price target to US$40.00 from US$50.00.
U.S. Bancorp (USB): Citigroup maintained its Buy rating.
Upstart (UPST): BTIG maintained its Buy rating with a US$43.00 price target.
Valero Energy (VLO): Jefferies downgraded the stock from Buy to Hold and set a US$401.00 price target.
Vicor (VICR): Needham maintained its Buy rating with a US$320.00 price target.
Vicor (VICR): Roth Capital maintained its Buy rating with a US$375.00 price target.
Viking Therapeutics (VKTX): HC Wainwright maintained its Buy rating.
Viking Therapeutics (VKTX): Morgan Stanley maintained its Overweight rating.
Viking Therapeutics (VKTX): Oppenheimer set a US$120.00 price target.
Viridian Therapeutics (VRDN): RBC Capital Markets raised its price target to US$38.00 from US$36.00 while retaining an Outperform rating.
W.P. Carey (WPC): Benchmark initiated coverage with a Buy rating.
W.P. Carey (WPC): Jefferies initiated coverage with a Buy rating and a US$73.00 price target.
Wabash National (WNC): DA Davidson maintained its Buy rating with a US$20.00 price target.
Warner Bros. Discovery (WBD): Morgan Stanley raised its price target to US$31.00 from US$29.00 while retaining an Equal Weight rating.
West Pharmaceutical Services (WST): Morgan Stanley upgraded the stock to Overweight and raised its price target to US$400.00 from US$365.00.
Western Alliance Bancorporation (WAL): Citigroup lowered its price target to US$95.00 from US$98.00 while retaining a Buy rating.
Western Alliance Bancorporation (WAL): Raymond James initiated coverage with an Outperform rating and a US$90.00 price target.
Williams Companies (WMB): Capital One Financial initiated coverage with an Overweight rating and a US$92.00 price target.
Williams Companies (WMB): Melius Research initiated coverage with a Buy rating and a US$84.00 price target.
Xometry (XMTR): Raymond James set a US$120.00 price target.
Xometry (XMTR): Rosenblatt Securities raised its price target to US$120.00 from US$110.00 while retaining a Buy rating.
Yesway (YSWY): William Blair initiated coverage with an Outperform rating.
YETI (YETI): Canaccord Genuity set a US$45.00 price target.
STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.
Related research
American Analyst Updates: Nov 6th, 2026
American Analyst Updates: Nov 5th, 2026
American Analyst Updates: Nov 4th, 2026
A monthly perspective in your inbox.
Five research sections in the STA Research Professional Newsletter.